 |
市場調査レポート
商品コード
1351092
疱疹状皮膚炎の2030年までの市場予測：治療、投与経路、流通チャネル、地域別の世界分析Dermatitis Herpetiformis Market Forecasts to 2030 - Global Analysis By Treatment (Therapeutics, Dietary and Other Treatments), Route of Administration, Distribution channel and By Geography |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
| 疱疹状皮膚炎の2030年までの市場予測：治療、投与経路、流通チャネル、地域別の世界分析 |
|
出版日: 2023年09月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 175+ Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 図表
- 目次
Stratistics MRCによると、世界の疱疹状皮膚炎市場は予測期間中にCAGR 9.2％で成長しています。
疱疹状皮膚炎は、強いかゆみと灼熱感を特徴とする慢性の自己免疫疾患で、皮膚に発疹が生じる。グルテン過敏性腸症やグルテン消化異常であるセリアック病の患者が頻繁に発症します。疫学的には、主に若年成人が罹患するまれな疾患です。最終的な治療法は、厳格なグルテン除去食で、数カ月で皮膚の改善が期待できるが、グルテン除去食が唯一の治療法となるには数年かかるかもしれないです。
DermNet NZによると、15歳から40歳までの患者が発症する可能性があります。男性は女性よりも罹患しやすいです。
疱疹状皮膚炎の増加
疱疹状皮膚炎は激しいかゆみを伴う。長期にわたる自己免疫疾患であり、強いかゆみ、ほてり、皮疹が生じる。セリアック病、グルテン過敏性腸症、グルテンの消化に問題がある人がなりやすいです。疫学によれば、ほとんどが若年成人に発症するまれな病気です。ここでも、疱疹状皮膚炎の治療法を見つけるための投資が増加しているため、市場の急成長が期待されています。
治療に伴う合併症
しかし、患者は歯の問題を経験する可能性があります。さらに、疱疹状皮膚炎が疥癬と間違われる可能性もあります。治療薬のため、患者は貧血、骨粗鬆症、1型糖尿病、甲状腺の問題にも悩まされます。珍しい問題もあるが、運動失調や神経障害などの神経症状を引き起こす可能性もあります。ヘモグロビンの低下といったダプソン使用による悪影響は、喉の痛み、失神発作、めまい、さらには人によっては肝臓障害を引き起こす可能性があり、市場拡大を制限するもう一つの理由となっています。
有利な償還手続き
皮膚炎の罹患率の増加や新興国市場における有利な償還政策も、市場成長率に寄与すると予想されます。さらに、より良い、より経済的な治療を提供するための政府の取り組みや、この疾患の治療オプションに対する認知度の向上も、世界市場に影響を与えると予想されます。
高コスト
同市場は、治療費の高さによって大きな制約を受けています。患者は、処方薬や健康診断の受診を含む長期的なケアにかかる費用によって負担を強いられる可能性があり、これが最善の治療選択肢を利用する妨げとなる可能性があります。さらに、ジェネリック治療の選択肢の出現と厳しい規制上の制約により、業界は大きな影響を受けると予測されます。
COVID-19の影響：
コロナウイルス危機とそれに続く世界数カ国の封鎖は、主要な尿素サイクル障害治療企業に財政的な影響を与えています。さらに、民間ヘルスケア部門はパンデミックが最もダメージを与えた分野の一つです。パンデミックは、研究開発、生産、医薬品供給に関する世界市場に悪影響を与えました。加えて、一部の国では政府の閉鎖により、パンデミックは世界中の様々な企業の製薬産業の拡大に影響を及ぼしています。
予測期間中、外用剤セグメントが最大となる見込み
予測期間中、外用薬セグメントが最大となる見込みです。外用処方薬は通常、疱疹状皮膚炎の治療の第一選択薬です。これらはローション、クリーム、坐薬などの形状になります。このような即時性は、迅速な獲得と実質的な行動維持につながり、市場のセグメント成長を促進すると予想されます。
予測期間中、小売薬局セグメントのCAGRが最も高くなると予想される
予測期間中、小売薬局セグメントは最も高いCAGRが見込まれます。疱疹状皮膚炎の治療薬は、一般的に小売薬局でジェネリック医薬品として入手可能です。また、小売薬局では、自宅へのドラッグデリバリーや、幅広い種類の医薬品・薬剤の入手といった便利なサービスが提供されています。さらに、脂質調整薬市場の拡大は、多忙なライフスタイルやストレスの多い仕事のスケジュールにより、製品を迅速に入手したいという消費者の需要によって後押しされると予想されます。
最大のシェアを占める地域
北米は、遺伝性疾患や遺伝子変異関連疾患の増加により、予測期間中最大の市場シェアを占めると予測されます。これは主に、アトピー性皮膚炎の有病率の増加、患者層における治療意識の高さ、アトピー性皮膚炎産業の進歩に起因しています。また、製薬企業による新薬開発への取り組みが活発化していること、技術的進歩が見られること、採用率が高いことなども、患者がより良い治療を選択するのに役立っています。
CAGRが最も高い地域：
アジア太平洋地域は、患者の認知度が低いため、予測期間中に最も高いCAGRを維持すると予測されます。この背景には、急速に発展するヘルスケア技術の存在感、膨大な患者数、医療費の増加があります。各国の研究開発プロジェクトの増加、医療インフラの開発、技術的に高度な外科手術の受け入れの増加、政府のイニシアチブの高まりにより、予測期間中に市場は成長を示すと予想されます。
無料カスタマイズサービス：
本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：
- 企業プロファイル
- 追加市場プレイヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
- 地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
- 競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング
目次
第1章 エグゼクティブサマリー
第2章 序文
- 概要
- ステークホルダー
- 調査範囲
- 調査手法
- データマイニング
- データ分析
- データ検証
- 調査アプローチ
- 調査ソース
- 1次調査ソース
- 2次調査ソース
- 前提条件
第3章 市場動向分析
- 促進要因
- 抑制要因
- 機会
- 脅威
- 新興市場
- 新型コロナウイルス感染症（COVID-19）の影響
第4章 ポーターのファイブフォース分析
- 供給企業の交渉力
- 買い手の交渉力
- 代替品の脅威
- 新規参入業者の脅威
- 競争企業間の敵対関係
第5章 世界の疱疹状皮膚炎市場：治療別
- 療法
- 局所コルチコステロイド
- サルファ剤
- ダプソン
- 食事
- RTE食品
- ベーカリー製品
- パスタ
- その他の治療
第6章 世界の疱疹状皮膚炎市場：投与経路別
- 外用
- 経口
第7章 世界の疱疹状皮膚炎市場：流通チャネル別
- 小売店
- eコマース
- 薬局
- その他の流通チャネル
第8章 世界の疱疹状皮膚炎市場：地域別
- 北米
- 米国
- カナダ
- メキシコ
- 欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
- アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
- 南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
- 中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ
第9章 主な発展
- 契約、パートナーシップ、コラボレーション、合弁事業
- 買収と合併
- 新製品の発売
- 事業拡大
- その他の主要戦略
第10章 企業プロファイル
- Allergan
- 3B scientific
- Acros Organics
- Aidance Scientific
- AlliChem
- Aidance Scientific
- Canyon Bakehouse
- GlaxoSmithKline Pharmaceuticals Ltd.
- HBC Chem
- Ivy Fine chemicals
- Nostrum Laboratories Inc.
- Pfizer Inc.
- Shingles Skincare
- AbbVie Inc.
- Waterstone Technology
List of Tables
- Table 1 Global Dermatitis Herpetiformis Market Outlook, By Region (2021-2030) ($MN)
- Table 2 Global Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
- Table 3 Global Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
- Table 4 Global Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
- Table 5 Global Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
- Table 6 Global Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
- Table 7 Global Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
- Table 8 Global Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
- Table 9 Global Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
- Table 10 Global Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
- Table 11 Global Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
- Table 12 Global Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 13 Global Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
- Table 14 Global Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
- Table 15 Global Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
- Table 16 Global Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
- Table 17 Global Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
- Table 18 Global Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
- Table 19 Global Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)
- Table 20 North America Dermatitis Herpetiformis Market Outlook, By Country (2021-2030) ($MN)
- Table 21 North America Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
- Table 22 North America Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
- Table 23 North America Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
- Table 24 North America Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
- Table 25 North America Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
- Table 26 North America Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
- Table 27 North America Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
- Table 28 North America Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
- Table 29 North America Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
- Table 30 North America Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
- Table 31 North America Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 32 North America Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
- Table 33 North America Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
- Table 34 North America Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
- Table 35 North America Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
- Table 36 North America Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
- Table 37 North America Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
- Table 38 North America Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)
- Table 39 Europe Dermatitis Herpetiformis Market Outlook, By Country (2021-2030) ($MN)
- Table 40 Europe Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
- Table 41 Europe Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
- Table 42 Europe Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
- Table 43 Europe Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
- Table 44 Europe Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
- Table 45 Europe Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
- Table 46 Europe Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
- Table 47 Europe Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
- Table 48 Europe Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
- Table 49 Europe Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
- Table 50 Europe Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 51 Europe Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
- Table 52 Europe Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
- Table 53 Europe Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
- Table 54 Europe Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
- Table 55 Europe Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
- Table 56 Europe Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
- Table 57 Europe Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)
- Table 58 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Country (2021-2030) ($MN)
- Table 59 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
- Table 60 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
- Table 61 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
- Table 62 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
- Table 63 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
- Table 64 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
- Table 65 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
- Table 66 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
- Table 67 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
- Table 68 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
- Table 69 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 70 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
- Table 71 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
- Table 72 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
- Table 73 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
- Table 74 Asia Pacific Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
- Table 75 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
- Table 76 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)
- Table 77 South America Dermatitis Herpetiformis Market Outlook, By Country (2021-2030) ($MN)
- Table 78 South America Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
- Table 79 South America Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
- Table 80 South America Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
- Table 81 South America Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
- Table 82 South America Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
- Table 83 South America Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
- Table 84 South America Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
- Table 85 South America Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
- Table 86 South America Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
- Table 87 South America Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
- Table 88 South America Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 89 South America Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
- Table 90 South America Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
- Table 91 South America Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
- Table 92 South America Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
- Table 93 South America Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
- Table 94 South America Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
- Table 95 South America Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)
- Table 96 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Country (2021-2030) ($MN)
- Table 97 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
- Table 98 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
- Table 99 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
- Table 100 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
- Table 101 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
- Table 102 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
- Table 103 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
- Table 104 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
- Table 105 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
- Table 106 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
- Table 107 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 108 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
- Table 109 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
- Table 110 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
- Table 111 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
- Table 112 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
- Table 113 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
- Table 114 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)
According to Stratistics MRC, the Global Dermatitis Herpetiformis Market is growing at a CAGR of 9.2% during the forecast period. Dermatitis Herpetiformis is a chronic autoimmune illness marked by strong itching and burning sensations, resulting in a skin rash. People with celiac disease, a gluten-sensitive enteropathy or anomaly in gluten digestion, frequently have it. Epidemiologically speaking, it is a rare disease that primarily affects young adults. The final course of treatment entails a strict gluten-free diet, with which skin improvement is anticipated in a few months, though it might take years for the gluten-free diet to be the only course of treatment.
According to the DermNet NZ organisation, Patients between the ages of 15 and 40 may be affected. Males are more susceptible to the condition than females.
Market Dynamics:
Driver:
Increasing incidence of dermatitis herpetiformis
Patients with dermatitis herpetiformis have severe itching. It is a long-term autoimmune condition that results in intense itchiness, burning, and skin rashes. People with celiac disease, gluten-sensitive enteropathy, or issues with gluten digestion are more likely to experience it. It is a rare disease that mostly affects young adults, according to epidemiology. Again, due to increasing investments in finding treatments for dermatitis herpetiformis, the market is expected to grow rapidly.
Restraint:
Complications associated with treatment
Patients could, however, experience dental issues. Additionally, it's possible that dermatitis herpetiformis will be mistaken for scabies. Due to therapeutic medications, the patient also suffers anemia, osteoporosis, Type 1 diabetes, and thyroid issues. Although some of the problems are uncommon, there is a potential that they could result in neurological conditions including ataxia and neuropathy. The negative consequences of dapsone use, such as a drop in hemoglobin, which can cause sore throats, fainting spells, dizziness, and even liver problems in some people, are another reason that can limit market expansion.
Opportunity:
Advantageous reimbursement procedures
The increasing incidence of dermatitis and the favorable reimbursement policies in developing nations are also anticipated to contribute to the market growth rate. Additionally, it is anticipated that increased government efforts to provide better and more economical care as well as increased awareness of the disease's treatment options will have an impact on the global market.
Threat:
High cost
The market is severely constrained by the treatment's high cost. Patients may be burdened by the costs of long-term care, which may include prescription drugs and wellness visits, and this may prevent them from accessing the best possible treatment options. Furthermore, it is projected that the industry will be significantly impacted by the advent of generic treatment options and strict regulatory constraints.
COVID-19 Impact:
The corona virus crisis and subsequent lockdown in several nations worldwide have financially impacted major urea cycle disorders treatment firms. Moreover, the private healthcare sector is one of the areas that the pandemic has damaged the most. The pandemic has had a detrimental impact on the worldwide market regarding research and development, production, and pharmaceutical supply. In addition, due to government lockdowns in some countries, the pandemic has impacted the expansion of pharmaceutical industries of various corporations worldwide.
The topical segment is expected to be the largest during the forecast period
The topical segment is expected to be the largest during the forecast period. A topical prescription drug is usually the first line of treatment for dermatitis herpetiformis. These can be in the shape of lotions, creams, suppositories, and other things. Such immediacy leads to speedy acquisition and substantial behaviour maintenance, which is expected to drive segment growth in the market.
The retail pharmacies segment is expected to have the highest CAGR during the forecast period
The retail pharmacies segment is expected to have the highest CAGR during the forecast period. Medication for dermatitis herpetiformis is commonly available as a generic pharmaceutical in retail pharmacies. In addition, retail pharmacies provide convenient services such as medicine delivery to your home and the availability of a wide range of drugs and medicines. Furthermore, lipid-regulating medicines market expansion is expected to be boosted by consumer demand for quick availability of products due to busy lifestyles and stressful work schedules.
Region with largest share:
North America is projected to hold the largest market share during the forecast period, owing to increased inherited and genetic mutation related disorders. This is primarily attributed to increasing prevalence of atopic dermatitis, high treatment awareness among the patient population, and advancement in atopic dermatitis industry. The increasing initiatives taken by the pharmaceutical organizations to generate novel drugs, technological advancements and high adoption rate, which will help patients opt for better treatment.
Region with highest CAGR:
Asia Pacific is projected to hold the highest CAGR over the forecast period, due to the low awareness among patients. This is attributed to strong presence of rapidly developing healthcare technology, huge patient population and rise in healthcare expenditure. With the rise in R&D projects in countries, developing medical infrastructure, rise in acceptance of technologically advanced surgical procedures and rising government initiatives, the market is expected to witness growth over forecast period.
Key players in the market:
Some of the key players in Dermatitis Herpetiformis market include: Allergan, 3B scientific, Acros Organics, Aidance Scientific, AlliChem, Aidance Scientific, Canyon Bakehouse, GlaxoSmithKline Pharmaceuticals Ltd., HBC Chem, Ivy Fine chemicals, Nostrum Laboratories Inc., Pfizer Inc., Shingles Skincare, AbbVie Inc. and Waterstone Technology.
Key Developments:
In May 2023, AbbVie's aesthetics unit is growing its product catalog once again with a new FDA approval. The product, called Skinvive, nabbed an FDA nod this week and falls within Allergan's Juvederm dermal filler collection.
In May 2022, Sidekick and Pfizer launch digital therapeutics solution for Atopic Dermatitis. The solution will be rolled-out in the UK first, followed by Belgium, Norway, the Netherlands, Sweden, France, Ireland, and Japan.
In January 2022, AbbVie Inc. announced that the US FDA has approved RINVOQ (upadacitinib) for the treatment of severe atopic dermatitis in children and adults 12 years of age and older. RINVOQ is recommended for patients who have not responded to previous injection or tablet treatments.
Treatments Covered:
- Therapeutics
- Dietary
- Other Treatments
Route of Administrations Covered:
- Topical
- Oral
Distribution channels Covered:
- Retail stores
- E-Commerce
- Pharmacies
- Other Distribution channels
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Emerging Markets
- 3.7 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Dermatitis Herpetiformis Market, By Treatment
- 5.1 Introduction
- 5.2 Therapeutics
- 5.2.1 Topical Corticosteroids
- 5.2.2 Sulfa Drugs
- 5.2.3 Dapsone
- 5.3 Dietary
- 5.3.1 Ready-to-eat Meals
- 5.3.2 Bakery Products
- 5.3.3 Pasta
- 5.4 Other Treatments
6 Global Dermatitis Herpetiformis Market, By Route of Administration
- 6.1 Introduction
- 6.2 Topical
- 6.3 Oral
7 Global Dermatitis Herpetiformis Market, By Distribution channel
- 7.1 Introduction
- 7.2 Retail stores
- 7.3 E-Commerce
- 7.4 Pharmacies
- 7.5 Other Distribution channels
8 Global Dermatitis Herpetiformis Market, By Geography
- 8.1 Introduction
- 8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
- 8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
- 8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa
9 Key Developments
- 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 9.2 Acquisitions & Mergers
- 9.3 New Product Launch
- 9.4 Expansions
- 9.5 Other Key Strategies
10 Company Profiling
- 10.1 Allergan
- 10.2 3B scientific
- 10.3 Acros Organics
- 10.4 Aidance Scientific
- 10.5 AlliChem
- 10.6 Aidance Scientific
- 10.7 Canyon Bakehouse
- 10.8 GlaxoSmithKline Pharmaceuticals Ltd.
- 10.9 HBC Chem
- 10.10 Ivy Fine chemicals
- 10.11 Nostrum Laboratories Inc.
- 10.12 Pfizer Inc.
- 10.13 Shingles Skincare
- 10.14 AbbVie Inc.
- 10.15 Waterstone Technology
